Sumanta K. Pal, MD, FASCO, on Cabozantinib Efficacy in SWOG 1500 for Papillary RCC

Video

Pal discussed findings from the SWOG 1500 trial investigating sunitinib versus either cabozantinib, crizotinib, or savolitinib to treat patients with metastatic papillary RCC.

CancerNetwork® spoke with Sumanta K. Pal, MD, FASCO, at the 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium (GU) regarding the SWOG 1500 trial (NCT02761057) investigating sunitinib (Sutent) versus cabozantinib (Cabometyx), crizotinib (Xalkori), or savolitinib to treat patients with metastatic papillary renal cell carcinoma.

Transcription:

This is a really big study. This is the first time that we have a systemic therapy regimen that’s shown benefit in papillary kidney cancer. This is quite groundbreaking; truly, this is one of those findings that you can hear at ASCO GU over the weekend and take back to the clinic on Monday morning and implement. You know, the study is the first to show that a targeted therapy, or systemic therapy for that matter, has any benefit within this disease space. And specifically, we showed a significant benefit in progression-free survival response rate with cabozantinib over sunitinib.

I think that in SWOG 1500, one of the main messages is that there’s a rare disease embedded within every cancer type, whether it’s lung cancer, ovarian cancer, [or] breast cancer. I think SWOG 1500 really proves that we can band together and do studies that really get at the biology of those rare tumor types. So, I’d encourage investigators across disciplines to use our study as a model.

Reference:

Pal SK, Tangen C, Murchie I, et al. Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. J Clin Oncol. 2021;39(suppl 6):270. doi:10.1200/JCO.2021.39.6_suppl.270

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content